amifostine anhydrous has been researched along with topotecan in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| List, AF | 1 |
| Malmström, H; Peterson, C; Zackrisson, AL | 1 |
| Alberts, DS; Berek, JS; Garcia, DJ; Gold, MA; Hallum, AV; Walker, JL | 1 |
| Bernstein, ML; Devidas, M; Dickman, PS; Dubowy, R; Gebhardt, M; Goorin, A; Grier, HE; Lafreniere, D; Link, MP; Meyers, PA; Nicholas, R; Perlman, EJ; Souid, AK; Stine, K; Wainer, IW | 1 |
| Bot, BM; Garces, YI; Jett, JR; Kozelsky, TF; Mandrekar, SJ; Martens, JM; Moore, DF; Okuno, SH; Schild, SE; Soori, GS; Wender, DB | 1 |
2 review(s) available for amifostine anhydrous and topotecan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
New approaches to the treatment of myelodysplasia.
Topics: Amifostine; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Enzyme Inhibitors; Humans; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Prognosis; Proto-Oncogene Mas; Risk Factors; Severity of Illness Index; Thalidomide; Topotecan; Treatment Outcome | 2002 |
4 trial(s) available for amifostine anhydrous and topotecan
| Article | Year |
|---|---|
No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Area Under Curve; Chromatography, High Pressure Liquid; Drug Interactions; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Topotecan | 2002 |
Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Female; Genital Neoplasms, Female; Humans; Middle Aged; Neutropenia; Topotecan | 2003 |
Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Amifostine; Bone Neoplasms; Child; Child, Preschool; Cyclophosphamide; Female; Humans; Male; Sarcoma, Ewing; Topotecan | 2006 |
Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality Control; Quality of Life; Radiation-Sensitizing Agents; Radiotherapy Dosage; Topotecan | 2007 |
1 other study(ies) available for amifostine anhydrous and topotecan
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |